Sign in

    Chris Stott

    Senior Analyst at JPMorgan Chase & Co.

    Chris Schott is a Senior Analyst at JPMorgan Chase & Co., specializing in healthcare equity research with a primary focus on covering major pharmaceutical and biotechnology companies such as Perrigo, IDEXX Laboratories, Regeneron Pharmaceuticals, Teva Pharmaceutical Industries, and Biogen. He has a proven track record in delivering actionable investment insights, as evidenced by his regular issuance of price targets and ratings for leading sector names, and his recommendations are tracked for accuracy and returns by MarketBeat and similar platforms. Schott began his career in equity research over a decade ago and has held analyst roles covering various healthcare firms before joining JPMorgan Chase & Co., where he continues to build his reputation in the industry. He holds key professional credentials, including FINRA registration and relevant securities licenses, reflecting his commitment to compliance and expertise.

    Chris Stott's questions to Amneal Pharmaceuticals (AMRX) leadership

    Chris Stott's questions to Amneal Pharmaceuticals (AMRX) leadership • Q2 2025

    Question

    Catarina, on behalf of Chris Stott from JPMorgan Chase & Co., questioned the key drivers for the expected revenue acceleration in the second half of 2025 and sought Amneal's perspective on the potential impact of US tariffs on pharmaceutical imports.

    Answer

    CFO Tasos Konidaris attributed the expected second-half revenue growth to the cadence of new product introductions, building momentum from recent launches, and increased manufacturing capacity following facility upgrades. Co-CEO Chintu Patel discussed the potential for tariffs to be chaotic but noted Amneal is less impacted due to its significant US manufacturing footprint, emphasizing the company's advocacy for policies that support national security and US-based production.

    Ask Fintool Equity Research AI